



ASX / Media Release  
16 August 2021

## Invex Granted Key European Patent for Exenatide

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure (ICP), is pleased to announce the European Patent Office has notified Invex on the intention to grant the Company a European patent, designated patent number EP3188747 and titled “Elevated Intracranial Pressure Treatment.” The patent will be published on 8 September 2021.

As with the Company’s issued US patent, this additional European patent covers the use of GLP-1 receptor agonists, including Exenatide, in reducing elevated ICP associated with Idiopathic Intracranial Hypertension (IIH).

Dr Tom Duthy, Executive Director of Invex commented “The granting of a European patent is an important component of our overall intellectual property (IP) strategy for Exenatide in IIH and potentially other indications related to elevated ICP. This patent will provide protection until at least August 2035 and when considered in the context of our European orphan drug designation, which provides 10 years of market exclusivity for Exenatide in the treatment of IIH, confers a strong overall IP position for Invex in Europe, alongside a similar suite of IP held in the US.”

Invex estimates the total annual addressable market for IIH in Europe is approximately A\$960 million, growing at 3.4% per annum with no current European Medicines Agency (EMA) approved treatments for IIH available, despite significant patient quality of life impacts and healthcare costs associated with this condition.

- ENDS -

***This release dated 16 August 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.***

---

## For more information, please contact:

### Company/Investors

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

### Media

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter **@InvexThera\_ASX**

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Idiopathic Intracranial Hypertension (IIH)

---

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

## About Exenatide

---

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which received approval in the US and Europe for the treatment of type 2 diabetes in 2005 and 2006 respectively. Professor Alexandra Sinclair's research showed that GLP-1 receptors are expressed in the choroid plexus in the brain and that Exenatide can bind to these receptors and reduce secretion of cerebrospinal fluid. Current Exenatide dosage forms are not optimised for IIH.